A multicenter, open-label, Phase Ib-II study of elacestrant in combination with abemaciclib in women and men with brain metastases from estrogen receptor-positive, HER-2-negative metastatic breast cancer (ELECTRA).

Contact Information for Access

• vanesa.gregorc@inoc.it
• diletta.favero@inoc.it
• paola.martino@inoc.it

Status

ATTIVO

---

Objective of the study

This research study is being conducted to determine whether elacestrant is safe and well-tolerated when administered with another medication called abemaciclib. In the current phase of the study, researchers will also investigate the effect that elacestrant (with abemaciclib) will have on participants’ brain tumors.

ClinicalTrials.gov ID NCT05386108
Sponsor: Stemline Therapeutics, Inc.

Medication

Elacestrant in combination with Abemaciclib.

Who is eligible to participate in the study?

Patients who are 18 years of age or older and who meet the study’s eligibility criteria may participate in this study.
Patients with ER-positive, HER-2-negative cancer and at least one active, measurable brain metastasis as defined by RECIST version 1.1. Patients must have received prior therapy in the metastatic setting.

View the full study Back to search page